Last updated: 2026-09-16 12:18:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Unicycive Therapeutics, Inc. (UNCY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4,79, with a market capitalisation of $143,45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,71 to $8,74. This page covers its latest market performance, valuation, price trends and company information.
$143,45M | |
$4,80 | |
$87,30 | |
$2,02 | |
$4,71 | |
2,14K | |
1,51M | |
-- | |
$8,74 | |
$3,71 | |
-- | |
-- |
Unicycive Therapeutics, Inc. (UNCY) is trading at $4,79 in pre-market trading as of 2026-09-16 12:15:00, up 1,59% ($0,08) from the previous close of $4,71
Pre-market trading shows how investors are pricing UNCY before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Unicycive Therapeutics, Inc. (UNCY) moved from $5,16 to $4,79, representing a decline of 7,27% ($0,38).
The stock traded between $4,71 and $5,62 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 991,09 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 21,4%
UNCY is currently trading at $4,79, placing it 21,4% of the way from its 52-week low of $3,71 to its 52-week high of $8,74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Unicycive Therapeutics, Inc. (UNCY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.